Neuro-Compass

A free educational website for all healthcare professionals involved in the care of people with multiple sclerosis.

[Neuro-Compass @Neuro_Compass]

Mylan, a generic form of current #MS treatment dimethyl fumarate, given favourable court ruling in the US. https://t.co/pghwgyLKxF. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

New survey finds majority of people with #MS use complementary and alternative medicine. https://t.co/WgsS23uOF6. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Neurological disability, age and obesity found to be risk factors for severe COVID-19 in #MS patients, but not DMT exposure. https://t.co/8DR0pxUPJP. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Hookworm trial shows evidence of immune system regulation and potential benefit for #MS patients. https://t.co/6wnPRvIPaa. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Serum NfL levels may be predictive of long-term clinical outcomes in #MS. https://t.co/BqjHDIIVE7. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Enrolment begins for Phase I trial of potential new relapsing #MS treatment, SAR442168. https://t.co/1dlkxBK4B6. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Changes in UK COVID-19 advice announced for those shielding, which may include some #MS patients. https://t.co/QE5Fukp0ti. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

US and UK #MS patients at increased risk of depression compared with non-MS patients. https://t.co/gLWMYiU8WM. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Switching from natalizumab to another #MS DMT may increase risk of relapse. https://t.co/Zpwobr4Yof. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

FDA extends review process for potential new #MS drug ofatumumab by 3 months. https://t.co/rBugizW9rC. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Fatigue, sleep disturbance and pain may be first signs of #MS. https://t.co/TqZ9RAEUVh. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Lipid mediator profiles predict response to therapy with an oral frankincense extract in relapsing-remitting #MS. https://t.co/v0lFmdRbgh. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

People living in urban areas are 30% more likely to develop #MS than those living in rural areas. https://t.co/EoetoXxMal. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Potential new #MS drug ofatumumab shows a good efficacy and safety profile in latest data from phase III trials. https://t.co/vNUXBZxySZ. Visit Neuro-Compass for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Specific cognitive rehabilitation shown to have real-world benefit on cognitive functioning in #MS. https://t.co/REEwQh7Sc9. Visit Neuro-Compass for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

EMA approves reduced infusion time for #MS patients taking ocrelizumab. https://t.co/5ThjK9QgoS. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

A new study of people with #MS in England shows they are at increased risk of cardiovascular disease. https://t.co/AptAhX1Arw. Visit Neuro-Compass for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Higher levels of blood NfL associated with the risk of worse #MS disability over time. https://t.co/5CPOLP8nlN. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

European Commission approves ozanimod for the treatment of adults with active relapsing-remitting #MS. https://t.co/pHdIjIa2tC. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!

[Neuro-Compass @Neuro_Compass]

Increases in disability reduced by long-term fingolimod use for secondary progressive #MS patients. https://t.co/WiHjpO9K52. Visit https://t.co/Zzks4Gdnwz for up to date expert-led #MS content!